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Abstract 
Background: The new direct-acting antiviral agents (DAAs) with high efficacy, low resistance, and low rate of 
adverse events (AEs) have shown promising outcomes for hepatitis C virus (HCV) treatment. This study assessed 
the efficacy and safety of Daclatasvir/Sofosbuvir (DCV/SOF) compared to Ledipasvir/Sofosbuvir (LDV/SOF) 
in patients with HCV infection in the real-world setting in Iran. 
Materials and Methods: A total of 42 patients with HCV infection were treated with either LDV/SOF (genotype 
1) or DCV/SOF (genotypes 1, 3 or unknown) with or without ribavirin (RBV). Assessment of risk factors, 
laboratory tests, sustained virologic response at post-treatment week 12 (SVR12), and AEs were performed. 
Results: The highest risk factor for HCV transmission was major surgery (50.0%), followed by tattooing 
(40.5%), phlebotomy (40.5%), and dental surgery (40.5%). No statistically significant relationships between 
genotypes and risk factors were observed. In both treatment groups (LDV/SOF and DCV/SOF), all of the 
patients (100%) with or without cirrhosis and treatment-experience achieved SVR12. One patient with a 
history of failed LDV/SOF therapy achieved SVR12 following retreatment with DCV/SOF. Both treatment 
regimens were well-tolerated. No serious AEs or discontinuation due to AEs was observed. The most common 
AE across both treatment groups were fatigue (42.9%), followed by anxiety (28.6%). Numerically, more 
adverse events were found with the LDV/SOF regimen than with the DCV/SOF regimen. 
Conclusion: Our study showed an excellent safety and efficacy of DCV/SOF and LDV/SOF in Iranian patients 
infected with HCV. The incidence of AEs among patients treated with LDV/SOF was higher than those receiving 
SOF/DCV. 
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Introduction 
Hepatitis C virus (HCV) infection is a major cause of 
liver diseases, hepatic cirrhosis and hepatocellular 
carcinoma (HCC). Worldwide, over 170 million 
individuals are infected with HCV, and approximately 
71 million people had viraemic infections in 20151. In 
Iran, HCV prevalence is less than 0.5%, equating 
186500 people2. Before 2014, pegylated‐ interferon 
(PEG‐ IFN) in combination with ribavirin (RBV) was 
the only drug approved by the United States Food and 
Drug Administration (FDA) for HCV treatment3. 
However, limitations such as low sustained virologic 
response (SVR) rate and significant side effects have 
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restricted interferon-based therapy4. Since 2011, the 
new direct-acting antiviral agents (DAAs) with high 
efficacy, low resistance, and low rate of adverse 
events have shown promising outcomes for HCV 
treatment5, of which Sofosbuvir (SOF), Ledipasvir 
(LDV) and Daclatasvir (DCV) are currently available 
in Iran2. HCV genotypes (GTs) are diverse across the 
world with each one having a unique response to 
antiviral treatment6, 7. Globally, the most common 
genotype is HCV GT-1 (46%), and in Iran, GT-1 and 
3 are the major genotypes2, 5. Since 2014, LDV/SOF 
combination has been approved by the FDA to treat 
HCV infection genotypes 1, 4, 5, and 6 for patients 
with or without cirrhosis, HCC, and prior treatment5, 
8. DCV/SOF has been proven to be active against all 
common genotypes, and also can be safely effective 
for patients with HIV-HCV co-infection and advanced 
liver diseases9. Most real-world studies on DAAs are 
related to the West, and data from Asia or developing 
countries are limited. In this study, we assessed the 
efficacy and safety of SOF/DCV compared to 
SOF/LDV in patients with HCV infection, with or 
without cirrhosis and treatment experience in the real-
world setting in Iran. 
Methods 
Study design and participants: 
This was an open-label trial study of patients with 
chronic HCV infection, who visited Labbafinezhad 
Hospital between October 2017 and November 2018. 
Patients were treated with either LDV 60 mg plus SOF 
400 mg, once-daily for 12 weeks (genotype1), or DCV 
60 mg/SOF 400 mg once daily for 12 weeks (GT1, 3, 
or unknown genotype). Adding RBV or increase in the 
treatment duration may occur at the physician’s 
discretion. Adding RBV to the patient's treatment 
regimen might occur if the patient had either cirrhosis 
or HCV treatment experience. Patients were excluded 
from our study if they became pregnant during their 
treatment or did not complete their assigned treatment. 
Patient demographics, risk factors, serum viral load, 
HCV genotype, cirrhosis status, HCV treatment 
experience, HBV co-infection, laboratory tests and 
liver enzymes before treatment, end of treatment and 
12 weeks after end of treatment were reviewed from 
the patient’s clinical records. Liver cirrhosis was 
diagnosed based on clinical findings, laboratory 
results, biopsy or Fibroscan (liver stiffness value>13 
kPa).  
Assessment:  
The primary endpoint was defined by sustained 
virologic response at 12 weeks after end of treatment 
(SVR12). Adverse events (AEs) and abnormality in 
laboratory tests and liver enzymes were also assessed.  
Statistical analysis: 
Statistical analyses were performed using Chi-square 
test for categorical variables, and the Student’s t-test or 
the Mann-Whitney U test for continuous variables via 
the SPSS version 24.0. P values of < 0.05 were 
considered statistically significant. 
Ethics:  
This study was approved by the Ethics Committee of 
Shahid Beheshti University of Medical Sciences and 
the Infectious Diseases and Tropical Medicine 
Research Center (approval number: 
Ir.sbmu.msp.rec.1397.131) which was in accordance 
with the Helsinki Declaration. 
Results 
Baseline characteristics: 
Of the 45 patients who were screened across our study, 
one patient became pregnant at week 5 of treatment, 
and was removed from our cohort, and 2 were lost to 
follow-up. Of the 42 remaining patients, 35 were 
treatment-naïve, and 7 were treatment-experienced. 
Among the treatment-experienced patients, 3 received 
LDV/SOF for 12 weeks, 2 received DCV/SOF for 12 
weeks, one patient with cirrhosis received 
LDV/SOF/RBV for 12 weeks, and one received 
DCV/SOF/RBV for 24 weeks. Treatment-naïve 
patients were as follows: 18 received LDV/SOF for 12 
weeks, one received DCV/SOF for 24 weeks, 4 with 
cirrhosis received LDV/SOF/RBV for 12 weeks, one 
received DCV/SOF/RBV for 12 weeks, and one with 
cirrhosis received DCV/SOF/RBV for 24 weeks, 10 
received DCV/SOF for 12 weeks (figure 1). One patient 
in the LDV/SOF group had co-infection with HBV-
HCV.  
Overall, HCV genotypes were as follows: 1a (15/42; 
35.7%), 1a/1b (14/42; 33.3%), 3a (8/42; 19.0%) and 
11.9% (5/42) were unknown. In the LDV/SOF group, 
50.0% (13/26) of patients were GT 1a, and the rest 
(13/26) were GT 1a/1b. In the DCV/SOF group, the 
most common GT was 3a (8/16; 50.0%), followed by 
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unknown (5/16; 31.3%), 1a (2/16; 12.5%), 1a/1b 
(1/16; 6.3%). 9.5% of patients had a platelet count of 
less than 90,000 per mm³. 2.4% had an albumin level 
≤ 3.5 g/dL. No patients had both a platelet count of 
less than 90,000 per mm³ and an albumin level of less 
than 3.5 g/dL. 35.7% and 16.7% had an ALT and AST 
level of more than 1.5 x ULN, respectively. 14.3% had 
both an ALT and AST level of more than 1.5 x ULN. 
There were no significant differences in baseline 
characteristics of patients between two treatment 
groups (table 1).  
Overall, the highest risk factor for HCV transmission 
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was major surgery (50.0%; 21/42), followed by 
tattooing (40.5%; 17/42), phlebotomy (40.5%; 17/42), 
dental surgery (40.5%; 17/42), and history of IV-drug 
use (33.3%; 14/42) (Figure 2). No statistically 
significant relationships between genotypes and risk 
factors were observed (Table 2). 
Efficacy: 
In the LDV/SOF group with or without RBV, all 26 
patients (13 patients with subtype 1a, 13 with subtype 
1a/1b) (100%) achieved SVR12. Among the 16 
patients (8 individuals with GT-3, 3 with GT-1, 5 with 
unknown genotype) who received DCV/SOF with and 
without RBV, the rate of SVR12 was 100%. One 
patient with an unknown genotype and a history of 
failed LDV/SOF therapy achieved SVR12 following 
retreatment with DCV/SOF. No SVR12-related P 
value was computed since SVR12 was a constant. 
Safety: 
Overall, of the 42 patients, 25 (59.5%) had at least one 
adverse event (AEs), of whom 9 (56.2%) and 16 
(61.5%) were in the DCV/SOF and LDV/SOF groups, 
respectively. The most common AEs across both 
treatment groups were as follows: fatigue (42.9%), 
anxiety (28.6%), myalgia (21.4%), muscle cramp 
(16.7%), musculoskeletal pain (14.3%). No patients 
discontinued treatment due to AEs. Similar proportion 
of patients with at least one AE was observed in two 
treatment groups (9 (56.2%) versus 16 (61.5%)). 
Numerically, more adverse events were found with the 
LDV/SOF regimen than with the DCV/SOF regimen 
(arthralgia (15.4% versus 6.3%), muscle cramp (19.2% 
versus 12.5%), rash (15.4% versus 6.3%), myalgia 
(30.8% versus 6.3%), pruritus (19.2% versus 0%), 
edema in limbs (11.5% versus 0%), musculoskeletal 
pain (19.2% versus 6.3%), GI symptoms (7.7% versus 
0%), depression (15.4% versus 6.3%), paresthesia 
(11.5% versus 6.3%). Numerically, no higher rate of 
AEs was observed in patients with RBV-containing 
regimen or 24 weeks of treatment than those not 
receiving RBV or treated for 12 weeks. Totally, there 
were no hemoglobin levels <10 g/dL, no platelet count 
of less than 50,000, no AST/ALT elevations > 5.0 x  
 
 



























DCV/SOF Regimen N=16 LDV/SOF Regimen N=26 Total N=42
Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus …                         Shokatpour et al. 
NBM 175 Novelty in Biomedicine 2020, 4, 171-81 
 
Table 1: Baseline characteristics of patients treated with SOF/DCV or SOF/LDV. 
Baseline patient characteristics LDV/SOF Group DCV/SOF Group P value 
Sex (male), no % 19 (73.1) 14 (78.5) 0.224 
Age – yr 49.08±2.929 44.79±2.993 0.353 
Baseline viral load, no % 
  ≤2,000,000       IU/mL 








Cirrhosis, no % 5 (19.2) 1 (6.3) 0.380 
Fibrosis, no % 3 (11.5) 0 0.275 

































Adding RBV, no % 5 (19.2) 3 (18.8) 1.00 
Albumin g/dL , 
median (range) 
4.6(3.5-5.2) 4.6(4.2-6.7) 0.084 
Albumin ≤3.5 g/dL, no % 1(3.8) 0  
Hemoglobin g/dL ,  
median (range) 
14.1(9.5-17.7) 14.2(12.8-17.4) 0.277 
INR ,median (range) 1.1(.9-2.1) 1.1(1-1.6) 0.485 
PT second, median (range) 12.5(9.6-15.6) 12(9-17) 0.313 
Bilirubin mg/dL , 
median (range) 
1(.3-2.1) 1(.5-5.1) 0.647 
Platelets  x 10³ per mm³, 
Median (range) 
206.5(45-350) 242(78-320) 0.398 
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Platelet count≤90,000 per mm³, no % 2 (7.7) 
 
2 (12.5)  
ALT  IU/L, median (range) 40.5(17-123) 41(15-149) 0.826 
ALT > 1.5 x ULN, no %  9 (34.6) 6 (37.5)  
AST  IU/L, median (range) 34(16-245) 38.5(20-119) 0.826 
AST > 1.5 x ULN, no % 5 (19.2) 2 (12.5)  
ULN, no bilirubin levels > 2.5 x ULN, and no INR > 
2.0 x ULN at 12 weeks after end of treatment (table 3, 
figure 3) 
Discussion 
In the present study, distribution of HCV subtypes was 
as follows: 1a (35.7%), 1a/1b (33.3%), 3a (19.0%) and 
11.9% were unknown. This result was consistent with 
a study by Jahanbakhsh Sefdi et al., performed on 
11,561 chronically HCV infected patients in Iran, 
reporting that subtype 1a (44.9%) was the most 
common subtype6. Nonetheless, it is in contrast to 
observations in other studies in Iran by Ranjbar 
Kermani et al.10, Sofian et al.11, and Ansari et al.12, 
which showed the prevalence of subtype 3a was 
61.3%, 52.9%, 52.0%, respectively.  
Some studies revealed that HCV mixed-genotype 
infection may lead to severe disease, unresponsiveness 
to antiviral treatment or relapse after antiviral therapy6, 
13. Our data showed a high rate of mixed HCV infection 
subtype 1a/1b (33.3%), which is comparable with the 
finding by Sofian et al.11 and Rafiei et al.14, that found 
the presence of subtype 1a/1b was 17.8% and 8.2% in 
Iranian patient populations, respectively. Moreover, a 
study by Ansari et al.12 in Iran demonstrated a high rate 
of mixed-genotype infections (20.0%). Nevertheless, 
our result is in contrast to other Iranian studies6, 10, 
stating that no or a few mixed infections were observed. 
It seems that the prevalence of mixed HCV infections 
are due to different studied populations, genotyping  
Table 2: Risk factor distribution according to HCV genotypes. 
  HCV genotypes, NO (%)     
Risk factors 1a,15 (100) 
1a/1b, 
14 (100) 3a, 8 (100) Total, N=37 P value 
Major surgery 8 (53.3) 9 (64.3) 4 (50.0) 21 (56.8) 0.834 
tattooing 4 (26.7) 5 (35.7) 5 (62.5) 14 (37.8) 0.382 
phlebotomy 6 (40.0) 6 (42.9) 6 (75.0) 18 (48.6) 0.356 
dental surgery 6 (40.0) 7 (50.0) 3 (37.5) 16 (43.2) 0.860 
history of IV addiction 4 (26.7) 3 (21.4) 2 (25.0) 9 (24.3) 0.921 
HBV vaccination 3 (20.0) 6 (42.9) 6 (75.0) 15 (40.5) 0.358 
history of blood transfusion 3 (20.0) 3 (21.4) 3 (37.5) 9 (24.3) 0.476 
extra marital sexual contacts 2 (13.3) 3 (21.4) 3 (37.5) 8 (21.6) 0.828 
family history of HCV 1 (6.7) 3 (21.4) 3 (37.5) 7 (18.9) 0.261 
using a common syringe 0 1 (7.1) 0 1 (2.7) 0.446 
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Table 3: Adverse events during treatment. 






patients with at least 1 AE 9 (56.2) 16(61.5) 25(59.5) 
serious AE 0 0 0 
death 0 0 0 
AE leading to discontinuation 0 0 0 
fatigue 7 (43.8) 11 (42.3) 18 (42.9) 
anxiety 4 (25.0) 8 (30.8) 12 (28.6) 
arthralgia 1 (6.3) 4 (15.4) 5 (11.9) 
muscle cramp 2 (12.5) 5 (19.2) 7 16.7) 
rash 1 (6.3) 4 (15.4) 5 (11.9) 
myalgia 1 (6.3) 8 (30.8) 9 (21.4) 
pruritus 0 5 (19.2) 5 (11.9) 
edema in limbs 0 3 (11.5) 3 (7.1) 
GI symptoms 0 2 (7.7) 2 (4.8) 
Musculoskeletal pain 1 (6.3) 5 (19.2) 6 (14.3) 
depression  1 (6.3) 4 (15.4) 5 (11.9) 
dry skin 1 (6.3) 2 (7.7) 3 (7.1) 
paresthesia 1 (6.3) 3 (11.5) 4 (9.5) 
cough 1 (6.3) 0 1 (2.4) 
asthenia 1 (6.3) 1 (3.8) 2 (4.8) 
Hyperthyroidism 0 1 (3.8) 1 (2.4) 
severe weight loss   1 (6.3) 0 1 (2.4) 
Laboratory abnormalities 
Platelet count≤ 50,000 per mm³, n % 0 0 0 
Hemoglobin level, n % 
< 10 g/dL 










INR > 2.0 x ULN, n %   0 0 0 
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Bilirubin > 2.5 x ULN, n %   0 0 0 
ALT    
> 2.5 x ULN, n % 











> 2.5 x ULN, n % 











methods, and rout of transmission12, 13. 
The results of this study indicated that the highest risk 
factor for HCV transmission was major surgery 
(50.0%), followed by tattooing (40.5%), phlebotomy 
(40.5%), dental surgery (40.5%), and history of IV-
drug use (33.3%). Nevertheless, our finding is in 
contrast to observations by other Iranian studies 2, 15-
17, showing intravenous drug users (IVDUs) were the 
main population at risk of HCV infection. This 
difference may be due to our small size of studied 
population (Figure 2).  
Numerous investigators demonstrated that the route of 
HCV transmission may affect the HCV genotype 
distribution 18, 19. In our data, the most common risk 
factor for subtype 1a was major surgery (8/15, 53.3%), 
followed by dental surgery (6/15, 40.0%), and 
phlebotomy (6/15, 40.0%). In our patients with HCV 
subtype 1a/1b, the risk factors were as follows: major 
surgery (64.3%, 9/14), dental surgery (50%, 7/14), 
phlebotomy (42.9%, 6/14), tattooing (35.7%, 5/14). 
The authors presumed that there may be an association 
between surgery and HCV infection GT 1 although 
there was no statistically significant difference (Table 
2). This finding is similar to some recent studies 20-22, 
which reported an association between surgery and 
GT 1. In patients with subtype 3a, the highest risk 
factor was phlebotomy (6/8, 75.0%), followed by 
tattooing (5/8, 62.5%), although no statistically 
significant relationships were observed (Table 2). Our 
result is in consistent with a study in Iran 10, and 
France 23 , showing an association between tattooing 
and subtype 3a. However, our finding is in contrast to 
some studies 18, 19, 21 demonstrating that IV-drug users 
may be associated with GT 1 and 3.  
In the management of HCV-GT 1 infection, the 
LDV/SOF regimen with or without ribavirin (RBV) can 
be applied for non-cirrhotic patients or those with 
compensated cirrhosis 24. Our real-world data of 
patients with HCV GT-1 (13 patients with subtype 1a, 
13 with subtype 1a/1b), who received SOF/LDV with 
or without RBV, showed that the SVR12 rate was 
100%. Our result showed a higher rate of SVR12 than 
those reported from clinical trials and other real life 
studies around the world 5, 24-28, which demonstrated the 
SVR12 rates were generally 91% to 98%. However, our 
data was similar to a study in India, which showed 
SVR12 was 100% in 145 HCV GT-1 patients treated 
with LDV/SOF with or without RBV 26. 
Some investigators reported that in HCV GT-1 patients 
treated with LDV/SOF, cirrhosis may lead to lower 
SVR12 rate due to lower drug delivery, altered drug 
metabolism, and impaired immune response 5, 27. 
Increase in treatment duration to 24 weeks or addition 
of RBV may help to improve the SVR12 rate in these 
patients 5. In our study, 4 cirrhotic, HCV GT-1 patients 
treated with 12 weeks of LDV/SOF plus RBV, and one 
patient with cirrhosis, HCV-treatment experience, and 
GT-1 who received a 12-week treatment with 
LDV/SOF plus RBV, achieved SVR12. It seems that 
the addition of RBV may be a benefit to improve the 
SVR12 rate in cirrhotic patients especially in situations 
in which next generation DDAs are not available. 
In the current study, among the 16 patients (8 
individuals with GT-3, 3 with GT-1, and 5 with 
unknown genotype) who received DCV/SOF with and 
without RBV, the rate of SVR12 was 100%. Our data 
was comparable to the findings from clinical trials and 
other real-life studies across the world 9, 26, 29-33, which 
showed a high efficacy of DCV/SOF with or without 
RBV. 
Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus …                         Shokatpour et al. 
NBM 179 Novelty in Biomedicine 2020, 4, 171-81 
In the present study, one patient with an unknown 
genotype and a history of failed LDV/SOF therapy 
achieved SVR12 following retreatment with 
DCV/SOF. A possible reason for failure with 
LDV/SOF may be due to viral genotype. Studies 
showed that the SVR rate for HCV GT-3 patients 
receiving LDV/SOF is low (approximately 62.0%) 2. 
Moreover, resistance-associated substitutions may 
lead to different resistance fold changes in different 
DAA-based regimens 1. No common AEs were 
observed during retreatment with DCV/SOF.  
The authors presume that the high rate of SVR12 
(100%) in both treatment groups (LDV/SOF and 
DCV/SOF) in our study may be due to the small 
number of patients, having no HCV GT-3 patients 
with cirrhosis (difficult to treat patients), and no or 
few patients are co-infected with HBV or HIV. 
In our study, both treatment regimens (LDV/SOF and 
DCV/SOF) were well-tolerated. No serious AEs or 
discontinuation due to AEs were observed. At least 
one adverse event occurred in 61.5% (16/26) and 
56.2% (9/16) of patients in the LDV/SOF and 
DCV/SOF groups, respectively. Our result showed a 
lower risk of AEs than report from the ION phase 3 
study 24, which observed treatment –related AEs in 
74% of non-cirrhotic patients treated with LDV/SOF 
and 88% of cirrhotic patients who received LDV/SOF 
plus RBV. In our data, no higher rate of AEs were 
observed in patients with RBV-containing regimen or 
24 weeks of treatment than those not receiving RBV 
or treated for 12 weeks. However, our result is in 
contrast to the phase 3 studies which reported a higher 
incidence of AEs among the patients treated with 
LDV/SOF plus RBV than those treated with 
LDV/SOF alone 24. In the LDV/SOF group, the most 
common adverse event was fatigue (42.3%), followed 
by anxiety (30.8%), myalgia (30.8%), muscle cramp 
(19.2%), pruritus (19.2%), and musculoskeletal pain 
(19.2%). Among the patients treated with SOF/DCV, 
the major adverse event was fatigue (43.8%), followed 
by anxiety (25.0%). Numerically, more adverse events 
were found with the LDV/SOF regimen than with the 
DCV/SOF regimen.  
In our study, there were several limitations. First, the 
small number of patients in two treatment groups, and 
subgroups with cirrhosis and prior treatment-
experience which limits the comparison between 
them. Second, lack of RAS testing which limits the 
analysis of the impact of resistance-associated 
substitutions on the efficacy of treatment. 
Conclusion 
Our study showed an excellent safety and efficacy of 
DCV/SOF and LDV/SOF in Iranian patients infected 
with HCV. Although, the incidence of AEs among the 
patients treated with LDV/SOF was higher than those 
receiving SOF/DCV. The highest risk factor for HCV 
transmission was major surgery (50.0%), followed by 
tattooing (40.5%), phlebotomy (40.5%), dental surgery 
(40.5%), and history of IV-drug use (33.3%). Further 
research in a real-world setting is needed to investigate 
the effect of baseline patient characteristics, viral 
mixed-genotypes and resistance-associated 
substitutions on sustained virologic response. 
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